Loss of endothelial cell FAK represses cisplatin-induced vascular senescence in distal niches to reduce lung metastatic burden

Chemotherapy is often imagined as a precise strike against cancer, a weapon that targets only the rogue cells growing out of control. In reality, the drugs travel through the entire body, affecting healthy tissues just as they do the tumor. One of the most common drugs used to treat lung cancer is cisplatin, a powerful agent that damages the DNA of cells to stop them from dividing. While this approach kills many cancer cells, it can also leave behind a dangerous side effect: it sometimes changes the environment where the cancer might spread, making it easier for the disease to return in a more aggressive form. Scientists have long known that the tiny blood vessels lining our organs are not just passive pipes for blood; they are active participants in health and disease, capable of sending signals that influence how nearby cells behave. When these vessels are stressed by treatment, they can inadvertently create a welcoming home for cancer cells that have escaped the original tumor, a process that leads to metastasis, the spread of cancer to distant parts of the body.

A new study from researchers at Barts Cancer Institute and other institutions in the United Kingdom reveals a specific mechanism behind this dangerous side effect. They discovered that a protein called focal adhesion kinase, or FAK, which sits inside the cells lining the blood vessels, acts as a critical switch. When lung cancer patients receive cisplatin, the drug damages the DNA of these blood vessel cells. In response, the FAK protein moves into the nucleus of the cell, the command center, and helps the cell survive the damage by activating repair systems. However, this survival comes at a cost. The cells do not simply repair themselves and return to normal; instead, they enter a state of permanent aging, known as senescence. These aging blood vessel cells begin to secrete a cocktail of chemicals that makes the lung tissue sticky and attractive to cancer cells, effectively priming the lung to catch and hold onto any cancer cells that arrive. The researchers found that if they removed the FAK protein from the blood vessel cells, or stopped it from working, the cells could not enter this dangerous aging state. Instead, the damaged cells died off, and the lung remained a hostile environment for cancer, significantly reducing the amount of metastasis.

To uncover this, the team worked with mice that had been engineered to develop lung cancer. They used a special genetic switch to turn off the FAK protein specifically in the blood vessel cells of some mice, while leaving it active in others. They then treated all the mice with cisplatin. In the mice where the FAK protein remained active, the drug successfully shrank the primary tumor, but it also triggered a chain reaction in the blood vessels of the lungs. The researchers observed that the blood vessel cells in these mice accumulated DNA damage and began to express markers of aging. These cells started producing a secret mixture of proteins that increased the stickiness of the vessel walls. When the researchers injected cancer cells directly into the bloodstream of these mice, the cancer cells latched onto the lung vessels and formed new tumors much more easily than they did in mice without the drug treatment.

In contrast, the mice that lacked the FAK protein in their blood vessels responded very differently. Even though they received the same dose of cisplatin, their blood vessel cells did not enter the aging state. The DNA damage that occurred did not trigger the same survival signals. Instead, without the FAK protein to guide the repair process, the damaged blood vessel cells were more likely to die. This meant the lung environment did not become sticky or welcoming to cancer. When the researchers tested this by injecting cancer cells into the bloodstream, they found that far fewer cancer cells were able to stick to the lung vessels or grow into new tumors in the mice without FAK. The study showed that the loss of this single protein in the blood vessels was enough to block the drug-induced changes that usually help cancer spread, without harming the primary tumor's response to the treatment.

The researchers also looked closely at what happens inside the cell during the first few hours after the drug is administered. They found that cisplatin causes the FAK protein to rush into the nucleus of the blood vessel cell very quickly, within about forty-five minutes. Once there, it helps activate a key repair system that fixes the broken DNA. This repair process is what allows the cell to survive the initial hit from the drug and eventually settle into that harmful, aging state. When the researchers blocked the activity of FAK, this rapid nuclear movement did not happen, the repair system was not fully activated, and the cell could not survive the damage. This suggests that FAK is not just a passive bystander but an active driver that decides whether a damaged blood vessel cell will live to become a problem or die and be replaced.

The study also examined the specific chemicals these aging blood vessel cells release. Using advanced mass spectrometry, the team identified a list of proteins that were secreted only when the cells were treated with cisplatin and had active FAK. This list included factors known to break down barriers, increase inflammation, and make cells stickier. When FAK was blocked, this entire secretory program was shut down. The blood vessel cells did not release the signals that would normally attract cancer cells. This confirmed that the protein is essential for creating the chemical environment that supports metastasis. The researchers verified these findings in human cells grown in the lab, showing that the same process occurs in human blood vessel cells, reinforcing the relevance of the discovery to human patients.

This work challenges the traditional view that chemotherapy only affects the tumor. It shows that the treatment can reprogram the healthy tissue around it, turning the lung's blood vessels into a trap for cancer cells. The researchers suggest that targeting the FAK protein in blood vessels could be a way to prevent this side effect. By stopping the blood vessel cells from entering this specific type of aging state, doctors might be able to keep the lungs safe from new tumors while still using cisplatin to kill the original cancer. The study does not claim that this is a cure, but it provides a clear biological explanation for why some patients develop metastasis after treatment and points to a specific target that could be blocked to prevent it. The findings highlight the importance of looking beyond the tumor itself and considering how the body's own support systems react to therapy, offering a new path to improve outcomes for people with lung cancer.